NRx Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
NRx Pharmaceuticals's earnings have been declining at an average annual rate of -0.03%, while the Pharmaceuticals industry saw earnings growing at 9.7% annually.
Key information
-0.03%
Earnings growth rate
18.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Next Earnings Update | 14 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How NRx Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -30 | 14 | 13 |
| 30 Sep 23 | 0 | -36 | 18 | 15 |
| 30 Jun 23 | 0 | -39 | 20 | 16 |
| 31 Mar 23 | 0 | -37 | 23 | 15 |
| 31 Dec 22 | 0 | -40 | 27 | 17 |
| 30 Sep 22 | 0 | -60 | 68 | 19 |
| 30 Jun 22 | 0 | -88 | 77 | 21 |
| 31 Mar 22 | 0 | -81 | 83 | 23 |
| 31 Dec 21 | 0 | -93 | 75 | 20 |
| 30 Sep 21 | 0 | -108 | 35 | 18 |
| 30 Jun 21 | 0 | -76 | 25 | 16 |
| 31 Mar 21 | 0 | -76 | 13 | 13 |
| 31 Dec 20 | 0 | -52 | 11 | 11 |
| 30 Sep 20 | 0 | -8 | 6 | 7 |
Quality Earnings: B1Q is currently unprofitable.
Growing Profit Margin: B1Q is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: B1Q is unprofitable, and losses have increased over the past 5 years at a rate of 0.03% per year.
Accelerating Growth: Unable to compare B1Q's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: B1Q is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (3%).
Return on Equity
High ROE: B1Q's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.